{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:42:41Z","timestamp":1790106161890,"version":"4.0.1"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":60,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["03-006-2022-0052"],"award-info":[{"award-number":["03-006-2022-0052"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["CVON2015-01"],"award-info":[{"award-number":["CVON2015-01"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.thromres.2024.02.009","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:13:32Z","timestamp":1707956012000},"page":"74-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Current and potentially novel antithrombotic treatment in acute ischemic stroke"],"prefix":"10.1016","volume":"236","author":[{"given":"Angelique","family":"Ceulemans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri M.H.","family":"Spronk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"ten Cate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim H.","family":"van Zwam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"van Oostenbrugge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdolna","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.thromres.2024.02.009_bb0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ane.13093","article-title":"Recurrent ischemic stroke: incidence, predictors, and impact on mortality","volume":"140","author":"Khanevski","year":"2019","journal-title":"Acta Neurol. Scand."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.009_bb0010","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/17474930211065917","article-title":"World Stroke Organization (WSO): global stroke fact sheet 2022","volume":"17","author":"Feigin","year":"2022","journal-title":"Int. J. Stroke"},{"issue":"368","key":"10.1016\/j.thromres.2024.02.009_bb0015","article-title":"Management of acute ischemic stroke","volume":"13","author":"Phipps","year":"2020","journal-title":"BMJ"},{"issue":"2018","key":"10.1016\/j.thromres.2024.02.009_bb0020","article-title":"Stroke in the 21st century: a snapshot of the burden, epidemiology, and quality of life","volume":"27","author":"Donkor","year":"2018","journal-title":"Stroke Res Treat."},{"issue":"8","key":"10.1016\/j.thromres.2024.02.009_bb0025","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics-2021 update: a report from the American Heart Association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.thromres.2024.02.009_bb0030","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2174\/157340310791658730","article-title":"Cardioembolic stroke: clinical features, specific cardiac disorders and prognosis","volume":"6","author":"Arboix","year":"2010","journal-title":"Curr. Cardiol. Rev."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.009_bb0035","doi-asserted-by":"crossref","first-page":"8433","DOI":"10.1038\/s41598-021-87584-2","article-title":"First approach to distinguish between cardiac and arteriosclerotic emboli of individual stroke patients applying the histological THROMBEX-classification rule","volume":"11","author":"Roessler","year":"2021","journal-title":"Sci. Rep."},{"issue":"20","key":"10.1016\/j.thromres.2024.02.009_bb0040","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1056\/NEJMoa2107727","article-title":"A randomized trial of intravenous alteplase before endovascular treatment for stroke","volume":"385","author":"LeCouffe","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10329","key":"10.1016\/j.thromres.2024.02.009_bb0045","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(22)00014-9","article-title":"Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment (MR CLEAN-MED): an open-label, multicentre, randomised controlled trial","volume":"399","author":"van der Steen","year":"2022","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.thromres.2024.02.009_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133523","article-title":"Hypercoagulability is a stronger risk factor for ischaemic stroke than for myocardial infarction: a systematic review","volume":"10","author":"Maino","year":"2015","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.thromres.2024.02.009_bb0055","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12974-017-0792-y","article-title":"Blocking of platelet glycoprotein receptor Ib reduces \u201cthrombo-inflammation\u201d in mice with acute ischemic stroke","volume":"14","author":"Schuhmann","year":"2017","journal-title":"J. Neuroinflammation"},{"issue":"8","key":"10.1016\/j.thromres.2024.02.009_bb0060","article-title":"Soluble platelet release factors as biomarkers for cardiovascular disease","volume":"21","author":"Baidildinova","year":"2021","journal-title":"Front Cardiovasc Med."},{"issue":"11","key":"10.1016\/j.thromres.2024.02.009_bb0065","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1161\/01.STR.0000034398.34938.20","article-title":"Course of platelet activation markers after ischemic stroke","volume":"33","author":"Marquardt","year":"2002","journal-title":"Stroke"},{"issue":"6","key":"10.1016\/j.thromres.2024.02.009_bb0070","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1160\/TH06-12-0725","article-title":"Hyperresponsiveness of platelets in ischemic stroke","volume":"97","author":"Fateh-Moghadam","year":"2007","journal-title":"Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2024.02.009_bb0075","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1586\/ern.10.104","article-title":"Screening for coagulation disorders in patients with ischemic stroke","volume":"10","author":"de Lau","year":"2010","journal-title":"Expert Rev. Neurother."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.009_bb0080","first-page":"118","article-title":"Blood coagulation following an acute ischemic stroke","volume":"44","author":"Sfredel","year":"2018","journal-title":"Curr. Health Sci. J."},{"issue":"8986","key":"10.1016\/j.thromres.2024.02.009_bb0085","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(95)92339-X","article-title":"Does atrial fibrillation confer a hypercoagulable state?","volume":"346","author":"Lip","year":"1995","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.thromres.2024.02.009_bb0090","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1160\/TH17-07-0492","article-title":"Atherothrombosis and thromboembolism: position paper from the second Maastricht consensus conference on thrombosis","volume":"118","author":"Spronk","year":"2018","journal-title":"Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2024.02.009_bb0095","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe factor XI deficiency","volume":"111","author":"Salomon","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.thromres.2024.02.009_bb0100","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1161\/ATVBAHA.118.312102","article-title":"Prognostic hemostasis biomarkers in acute ischemic stroke","volume":"39","author":"Donkel","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.009_bb0105","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/1747493016654532","article-title":"Beyond antiplatelets: the role of glycoprotein VI in ischemic stroke","volume":"11","author":"Induruwa","year":"2016","journal-title":"Int. J. Stroke"},{"key":"10.1016\/j.thromres.2024.02.009_bb0110","article-title":"Fibrin-glycoprotein VI interaction increases platelet procoagulant activity and impacts clot structure","author":"Gauer","year":"2022","journal-title":"J Thromb Haemost [Internet]"},{"issue":"3","key":"10.1016\/j.thromres.2024.02.009_bb0115","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1161\/ATVBAHA.120.315030","article-title":"GPVI (glycoprotein VI) interaction with fibrinogen is mediated by avidity and the fibrinogen \u03b1C-region","volume":"41","author":"Xu","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2016","key":"10.1016\/j.thromres.2024.02.009_bb0120","article-title":"Platelet activation: the mechanisms and potential biomarkers","volume":"15","author":"Yun","year":"2016","journal-title":"Biomed. Res. Int."},{"issue":"17","key":"10.1016\/j.thromres.2024.02.009_bb0125","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/CIRCULATIONAHA.107.691279","article-title":"Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb\/IIIa blockade on infarct size, functional outcome, and intracranial bleeding","volume":"115","author":"Kleinschnitz","year":"2007","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.thromres.2024.02.009_bb0130","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1161\/STROKEAHA.115.011114","article-title":"Efficacy and safety of platelet glycoprotein receptor blockade in aged and comorbid mice with acute experimental stroke","volume":"46","author":"Kraft","year":"2015","journal-title":"Stroke"},{"issue":"15","key":"10.1016\/j.thromres.2024.02.009_bb0135","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1111\/bph.13178","article-title":"A novel snake venom-derived GPIb antagonist, anfibatide, protects mice from acute experimental ischaemic stroke and reperfusion injury","volume":"172","author":"Li","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.thromres.2024.02.009_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066960","article-title":"The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke","volume":"8","author":"Goebel","year":"2013","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.thromres.2024.02.009_bb0145","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1161\/ATVBAHA.115.306883","article-title":"The novel oral syk inhibitor, Bl1002494, protects mice from arterial thrombosis and thrombo-inflammatory brain infarction","volume":"36","author":"van Eeuwijk","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.009_bb0150","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00392-009-0109-y","article-title":"Glycoprotein VI as a prognostic biomarker for cardiovascular death in patients with symptomatic coronary artery disease","volume":"99","author":"Bigalke","year":"2010","journal-title":"Clin. Res. Cardiol."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.009_bb0155","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1468-1331.2009.02754.x","article-title":"Expression of platelet glycoprotein VI is associated with transient ischemic attack and stroke","volume":"17","author":"Bigalke","year":"2010","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.009_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262695","article-title":"Platelet surface receptor glycoprotein VI-dimer is overexpressed in stroke: the glycoprotein VI in stroke (GYPSIE) study results","volume":"17","author":"Induruwa","year":"2022","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.thromres.2024.02.009_bb0165","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3109\/09537104.2012.746455","article-title":"Plasma levels of soluble glycoprotein VI (sGPVI) are associated with ischemic stroke","volume":"24","author":"Wurster","year":"2013","journal-title":"Platelets"},{"issue":"4","key":"10.1016\/j.thromres.2024.02.009_bb0170","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005208.pub2","article-title":"Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke","author":"Ciccone","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.thromres.2024.02.009_bb0175","series-title":"StatPearls. Treasure Island","article-title":"Physiology, coagulation pathways","author":"Chaudhry","year":"2022"},{"issue":"7590","key":"10.1016\/j.thromres.2024.02.009_bb0180","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/bmj.38964.489051.80","article-title":"Atherothrombosis and ischaemic stroke","volume":"334","author":"Rothwell","year":"2007","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.thromres.2024.02.009_bb0185","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0049-3848(02)00331-6","article-title":"Observation on tissue factor pathway and some other coagulation parameters during the onset of acute cerebrocardiac thrombotic diseases","volume":"107","author":"He","year":"2002","journal-title":"Thromb. Res."},{"issue":"8","key":"10.1016\/j.thromres.2024.02.009_bb0190","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/ATVBAHA.107.141911","article-title":"Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis","volume":"27","author":"Mackman","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"12","key":"10.1016\/j.thromres.2024.02.009_bb0195","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1161\/ATVBAHA.108.177402","article-title":"Tissue factor in coagulation: which? where? when?","volume":"29","author":"Butenas","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.009_bb0200","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1515\/cclm-2016-0399","article-title":"Factor VIIa-antithrombin complex: a possible new biomarker for activated coagulation","volume":"55","author":"Spiezia","year":"2017","journal-title":"Clin. Chem. Lab. Med."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.009_bb0205","article-title":"Factor VII deficiency: clinical phenotype, genotype and therapy","volume":"6","author":"Napolitano","year":"2017","journal-title":"J Clin Med Res [Internet]"},{"issue":"6","key":"10.1016\/j.thromres.2024.02.009_bb0210","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1161\/01.ATV.0000130465.23430.74","article-title":"Role of tissue factor in hemostasis, thrombosis, and vascular development","volume":"24","author":"Mackman","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.thromres.2024.02.009_bb0215","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev-physiol-042210-121137","article-title":"Role of tissue factor in venous thrombosis","volume":"73","author":"Manly","year":"2011","journal-title":"Annu. Rev. Physiol."},{"issue":"5","key":"10.1016\/j.thromres.2024.02.009_bb0220","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s11883-012-0269-5","article-title":"Role of tissue factor in atherothrombosis","volume":"14","author":"Owens","year":"2012","journal-title":"Curr. Atheroscler. Rep."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.009_bb0225","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/STROKEAHA.115.008678","article-title":"Circulating tissue factor levels and risk of stroke: findings from the EPICOR study","volume":"46","author":"Iacoviello","year":"2015","journal-title":"Stroke"},{"issue":"6","key":"10.1016\/j.thromres.2024.02.009_bb0230","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1160\/TH09-08-0606","article-title":"Factor VIIa-antithrombin complexes in patients with arterial and venous thrombosis","volume":"103","author":"Spiezia","year":"2010","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.009_bb0235","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/1076029616631424","article-title":"Assessing circulating factor VIIa-antithrombin complexes in acute ischemic stroke: a pilot study","volume":"23","author":"S\u0142omka","year":"2017","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.009_bb0240","doi-asserted-by":"crossref","first-page":"105772","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.105772","article-title":"Changes in procoagulant blood biomarkers after mechanical thrombectomy","volume":"30","author":"Welch","year":"2021","journal-title":"J. Stroke Cerebrovasc. Dis."},{"issue":"5","key":"10.1016\/j.thromres.2024.02.009_bb0245","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/MBC.0b013e3283389513","article-title":"Polymorphisms in the factor VII gene and ischemic stroke in young adults","volume":"21","author":"Lopaciuk","year":"2010","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"1","key":"10.1016\/j.thromres.2024.02.009_bb0250","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/jth.13899","article-title":"Associations of activated coagulation factor VII and factor VIIa-antithrombin levels with genome-wide polymorphisms and cardiovascular disease risk","volume":"16","author":"Olson","year":"2018","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.009_bb0255","first-page":"1305","article-title":"Factor VII antigen levels are differentially associated to etiological subtypes of ischaemic stroke","volume":"110","author":"Stanne","year":"2013","journal-title":"Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2024.02.009_bb0260","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nm.2184","article-title":"Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases","volume":"16","author":"Massberg","year":"2010","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.009_bb0265","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/ana.24993","article-title":"Neutrophil extracellular traps in ischemic stroke thrombi","volume":"82","author":"Laridan","year":"2017","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.thromres.2024.02.009_bb0270","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1084\/jem.20052458","article-title":"Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis","volume":"203","author":"Kleinschnitz","year":"2006","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.009_bb0275","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/asheducation-2014.1.66","article-title":"Epidemiologic and clinical data linking factors XI and XII to thrombosis","volume":"2014","author":"Key","year":"2014","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"2","key":"10.1016\/j.thromres.2024.02.009_bb0280","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1084\/jem.20050664","article-title":"Defective thrombus formation in mice lacking coagulation factor XII","volume":"202","author":"Renn\u00e9","year":"2005","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.009_bb0285","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1016\/j.neuroimage.2009.11.061","article-title":"Enhanced cortical reperfusion protects coagulation factor XII-deficient mice from ischemic stroke as revealed by high-field MRI","volume":"49","author":"Pham","year":"2010","journal-title":"Neuroimage"},{"issue":"13","key":"10.1016\/j.thromres.2024.02.009_bb0290","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1161\/CIRCULATIONAHA.109.924761","article-title":"Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding","volume":"121","author":"Hagedorn","year":"2010","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.thromres.2024.02.009_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146783","article-title":"The coagulation factor XIIa inhibitor rHA-infestin-4 improves outcome after cerebral ischemia\/reperfusion injury in rats","volume":"11","author":"Krupka","year":"2016","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.thromres.2024.02.009_bb0300","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2040-7378-2-5","article-title":"COU254, a specific 3-carboxamide-coumarin inhibitor of coagulation factor XII, does not protect mice from acute ischemic stroke","volume":"2","author":"Kraft","year":"2010","journal-title":"Exp Transl Stroke Med."},{"issue":"3","key":"10.1016\/j.thromres.2024.02.009_bb0305","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12975-012-0186-5","article-title":"Inhibition of factor XII-mediated activation of factor XI provides protection against experimental acute ischemic stroke in mice","volume":"3","author":"Leung","year":"2012","journal-title":"Transl. Stroke Res."},{"issue":"5","key":"10.1016\/j.thromres.2024.02.009_bb0310","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/jth.12531","article-title":"Antigen levels of coagulation factor XII, coagulation factor XI and prekallikrein, and the risk of myocardial infarction and ischemic stroke in young women","volume":"12","author":"Siegerink","year":"2014","journal-title":"J. Thromb. Haemost."},{"issue":"12","key":"10.1016\/j.thromres.2024.02.009_bb0315","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1111\/jth.15092","article-title":"Coagu- lation factor XII, XI, and VIII activity levels and secondary events after first ischemic stroke","volume":"18","author":"Rohmann","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2024.02.009_bb0320","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1159\/000368434","article-title":"Regulation of blood coagulation factors XI and XII in patients with acute and chronic cerebrovascular disease: a case-control study","volume":"38","author":"Kraft","year":"2014","journal-title":"Cerebrovasc. Dis."},{"issue":"18","key":"10.1016\/j.thromres.2024.02.009_bb0325","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1161\/CIRCULATIONAHA.110.943738","article-title":"Intrinsic coagulation activation and the risk of arterial thrombosis in young women: results from the risk of arterial thrombosis in relation to Oral contraceptives (RATIO) case-control study","volume":"122","author":"Siegerink","year":"2010","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.thromres.2024.02.009_bb0330","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1055\/s-0040-1710013","article-title":"Role of factor XIa and plasma kallikrein in arterial and venous thrombosis","volume":"120","author":"Visser","year":"2020","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2024.02.009_bb0335","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/ana.24380","article-title":"Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation","volume":"77","author":"G\u00f6b","year":"2015","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.009_bb0340","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1124\/jpet.106.105064","article-title":"Selective inhibition of plasma kallikrein protects brain from reperfusion injury","volume":"318","author":"Storini","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.thromres.2024.02.009_bb0345","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s00018-022-04257-7","article-title":"Novel contact-kinin inhibitor sylvestin targets thromboinflammation and ameliorates ischemic stroke","volume":"79","author":"Zhang","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"issue":"3","key":"10.1016\/j.thromres.2024.02.009_bb0350","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1124\/jpet.116.238600","article-title":"Inhibition of factor XIa reduces the frequency of cerebral microembolic signals derived from carotid arterial thrombosis in rabbits","volume":"360","author":"Wang","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"11","key":"10.1016\/j.thromres.2024.02.009_bb0355","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1161\/STROKEAHA.118.022792","article-title":"Genetically determined FXI (factor XI) levels and risk of stroke","volume":"49","author":"Gill","year":"2018","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.thromres.2024.02.009_bb0360","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/MBC.0000000000000616","article-title":"Relation of coagulation factor XI with incident coronary heart disease and stroke: the Cardiovascular Health Study","volume":"28","author":"Appiah","year":"2017","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"1","key":"10.1016\/j.thromres.2024.02.009_bb0365","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ccep.2020.11.003","article-title":"Atrial fibrillation and stroke","volume":"13","author":"Essa","year":"2021","journal-title":"Card Electrophysiol Clin."},{"issue":"9","key":"10.1016\/j.thromres.2024.02.009_bb0370","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s40264-018-0668-9","article-title":"Non-bleeding adverse events with the use of direct oral anticoagulants: a sequence symmetry analysis","volume":"41","author":"Maura","year":"2018","journal-title":"Drug Saf."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.009_bb0375","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014376","article-title":"Ischemic stroke and transient ischemic attack risk following vitamin K antagonist cessation in newly diagnosed atrial fibrillation: a cohort study","volume":"9","author":"Martinez","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"12","key":"10.1016\/j.thromres.2024.02.009_bb0380","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.009_bb0385","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/23969873221076971","article-title":"Oral anticoagu- lation versus antiplatelet therapy for secondary stroke prevention in patients with embolic stroke of undetermined source: a systematic review and meta-analysis","volume":"7","author":"Hariharan","year":"2022","journal-title":"Eur. Stroke J."},{"key":"10.1016\/j.thromres.2024.02.009_bb0390","article-title":"Apixaban for TreatmenT of embolIC stroke of undetermined source - ATTICUS randomized trial - explorative analysis of AF burden in the ATTICUS cohort","volume":"9;44(Supplement_2)","author":"Geisler","year":"2023","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.thromres.2024.02.009_bb0395","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s10654-021-00751-7","article-title":"Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: a systematic review and meta-analysis","volume":"36","author":"Zhang","year":"2021","journal-title":"Eur. J. Epidemiol."},{"issue":"7","key":"10.1016\/j.thromres.2024.02.009_bb0400","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"issue":"8","key":"10.1016\/j.thromres.2024.02.009_bb0405","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.amjmed.2005.10.039","article-title":"Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials","volume":"119","author":"McQuaid","year":"2006","journal-title":"Am. J. Med."},{"issue":"9","key":"10.1016\/j.thromres.2024.02.009_bb0410","article-title":"Meta-analysis of oral anticoagulants and adverse outcomes in atrial fibrillation patients after intracranial hemorrhage","volume":"15","author":"Liu","year":"2022","journal-title":"Front Cardiovasc Med."},{"issue":"8","key":"10.1016\/j.thromres.2024.02.009_bb0415","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237022","article-title":"Major bleeding risk and mortality associated with antiplatelet drugs in real-world clinical practice. A prospective cohort study","volume":"15","author":"Bouget","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.thromres.2024.02.009_bb0420","article-title":"Comparison of clinical outcomes between ticagrelor and clopidogrel in acute coronary syndrome: a comprehensive meta-analysis","volume":"8","author":"Sun","year":"2021","journal-title":"Front Cardiovasc Med."},{"issue":"19","key":"10.1016\/j.thromres.2024.02.009_bb0425","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009856","article-title":"Comparison between aspirin and clopidogrel in secondary stroke prevention based on real-world data","volume":"7","author":"Chi","year":"2018","journal-title":"J. Am. Heart Assoc."},{"issue":"9038","key":"10.1016\/j.thromres.2024.02.009_bb0430","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"issue":"2019","key":"10.1016\/j.thromres.2024.02.009_bb0435","first-page":"1607181","article-title":"Benefits and risks of clopidogrel vs. aspirin monotherapy after recent ischemic stroke: a systematic review and meta-analysis","volume":"1","author":"Paciaroni","year":"2019","journal-title":"Cardiovasc. Ther."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.009_bb0440","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1161\/STROKEAHA.120.033033","article-title":"Dual antiplatelet therapy versus aspirin in patients with stroke or transient ischemic attack: meta-analysis of randomized controlled trials","volume":"52","author":"Bhatia","year":"2021","journal-title":"Stroke"},{"issue":"365","key":"10.1016\/j.thromres.2024.02.009_bb0445","article-title":"Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial","volume":"6","author":"Wang","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.thromres.2024.02.009_bb0450","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1177\/1747493017743051","article-title":"Complications of endo- vascular treatment for acute ischemic stroke: prevention and management","volume":"13","author":"Balami","year":"2018","journal-title":"Int. J. Stroke"},{"key":"10.1016\/j.thromres.2024.02.009_bb0455","article-title":"The next step in the treatment of stroke","volume":"11","author":"Matei","year":"2020","journal-title":"Front. Neurol."},{"issue":"25","key":"10.1016\/j.thromres.2024.02.009_bb0460","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2015-05-643338","article-title":"Low ADAMTS13 activity is associated with an increased risk of ischemic stroke","volume":"126","author":"Sonneveld","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2024.02.009_bb0465","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11239-019-01941-7","article-title":"ADAMTS13 activity is associated with early neurological improvement in acute ischemic stroke patients treated with intravenous thrombolysis","volume":"49","author":"Putzer","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"issue":"19","key":"10.1016\/j.thromres.2024.02.009_bb0470","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood-2015-08-662650","article-title":"ADAMTS13-mediated thrombolysis of t-PA-resistant occlusions in ischemic stroke in mice","volume":"127","author":"Denorme","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.thromres.2024.02.009_bb0475","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1182\/blood.2021012787","article-title":"Robust thrombolytic and anti-inflammatory action of a constitutively active ADAMTS13 variant in murine stroke models","volume":"139","author":"South","year":"2022","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.thromres.2024.02.009_bb0480","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.thromres.2024.02.009_bb0485","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1056\/NEJMoa2211113","article-title":"Recombinant ADAMTS13 for hereditary thrombotic thrombocytopenic purpura","volume":"387","author":"Asmis","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.009_bb0490","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1038\/s41467-020-17648-w","article-title":"Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs","volume":"11","author":"Wilbs","year":"2020","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.thromres.2024.02.009_bb0495","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/cts.13192","article-title":"Pharmacokinetic\/ pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312)","volume":"15","author":"Pawaskar","year":"2022","journal-title":"Clin. Transl. Sci."},{"issue":"10328","key":"10.1016\/j.thromres.2024.02.009_bb0500","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(21)02225-X","article-title":"Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"399","author":"Craig","year":"2022","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.thromres.2024.02.009_bb0505","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1093\/cvr\/cvac091","article-title":"What to expect from drug targeting factor XI?","volume":"118","author":"Nagy","year":"2022","journal-title":"Cardiovasc. Res."},{"issue":"7","key":"10.1016\/j.thromres.2024.02.009_bb0510","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10333","key":"10.1016\/j.thromres.2024.02.009_bb0515","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"issue":"10357","key":"10.1016\/j.thromres.2024.02.009_bb0520","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2024.02.009_bb0525","author":"Bayer"},{"issue":"23","key":"10.1016\/j.thromres.2024.02.009_bb0530","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2024.02.009_bb0535","doi-asserted-by":"crossref","DOI":"10.1038\/s41569-023-00872-4","article-title":"Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale","author":"Gigante","year":"2023","journal-title":"Nat Rev Cardiol [Internet]"},{"key":"10.1016\/j.thromres.2024.02.009_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2021.113804","article-title":"Targeting platelet glycoprotein VI attenuates progressive ischemic brain damage before recanalization during middle cerebral artery occlusion in mice","volume":"344","author":"Bieber","year":"2021","journal-title":"Exp. Neurol."},{"issue":"9","key":"10.1016\/j.thromres.2024.02.009_bb0545","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/jcph.1616","article-title":"Population pharmacokinetic\/pharmacodynamic modeling of glenzocimab (ACT017) a glycoprotein VI inhibitor of collagen-induced platelet aggregation","volume":"60","author":"Renaud","year":"2020","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.thromres.2024.02.009_bb0550","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1161\/ATVBAHA.118.312314","article-title":"Safety and tolerability, pharmacokinetics, and pharmacodynamics of ACT017, an antiplatelet GPVI (glycoprotein VI) fab","volume":"39","author":"Voors-Pette","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"Suppl. 2","key":"10.1016\/j.thromres.2024.02.009_bb0555","article-title":"ACTIMIS Trial: safety interim analysis data of glenzocimab, a novel antiplatelet agent on top of acute ischemic stroke standard of care","volume":"5","author":"Mazighi","year":"2021","journal-title":"Res Pract Thromb Haemost."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824000446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824000446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:26:15Z","timestamp":1777472775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824000446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":111,"alternative-id":["S0049384824000446"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.02.009","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and potentially novel antithrombotic treatment in acute ischemic stroke","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}